309 related articles for article (PubMed ID: 25997619)
1. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
[TBL] [Abstract][Full Text] [Related]
3. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
[TBL] [Abstract][Full Text] [Related]
4. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.
Ward C; Meehan J; Mullen P; Supuran C; Dixon JM; Thomas JS; Winum JY; Lambin P; Dubois L; Pavathaneni NK; Jarman EJ; Renshaw L; Um IH; Kay C; Harrison DJ; Kunkler IH; Langdon SP
Oncotarget; 2015 Sep; 6(28):24856-70. PubMed ID: 26259239
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.
Tafreshi NK; Lloyd MC; Proemsey JB; Bui MM; Kim J; Gillies RJ; Morse DL
Mol Imaging Biol; 2016 Apr; 18(2):219-31. PubMed ID: 26276155
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
9. The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression.
Stengel C; Newman SP; Leese MP; Thomas MP; Potter BV; Reed MJ; Purohit A; Foster PA
Anticancer Res; 2015 Oct; 35(10):5249-61. PubMed ID: 26408684
[TBL] [Abstract][Full Text] [Related]
10. Increased activation of the hypoxia-inducible factor pathway in varicose veins.
Lim CS; Kiriakidis S; Paleolog EM; Davies AH
J Vasc Surg; 2012 May; 55(5):1427-39. PubMed ID: 22277691
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA
Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138
[TBL] [Abstract][Full Text] [Related]
12. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Miao B; Ji Z; Tan L; Taylor M; Zhang J; Choi HG; Frederick DT; Kumar R; Wargo JA; Flaherty KT; Gray NS; Tsao H
Cancer Discov; 2015 Mar; 5(3):274-87. PubMed ID: 25542448
[TBL] [Abstract][Full Text] [Related]
13. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
14. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion.
Robertson N; Potter C; Harris AL
Cancer Res; 2004 Sep; 64(17):6160-5. PubMed ID: 15342400
[TBL] [Abstract][Full Text] [Related]
15. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Said HM; Hagemann C; Carta F; Katzer A; Polat B; Staab A; Scozzafava A; Anacker J; Vince GH; Flentje M; Supuran CT
Bioorg Med Chem; 2013 Jul; 21(13):3949-57. PubMed ID: 23706268
[TBL] [Abstract][Full Text] [Related]
17. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.
Kaluzová M; Kaluz S; Lerman MI; Stanbridge EJ
Mol Cell Biol; 2004 Jul; 24(13):5757-66. PubMed ID: 15199132
[TBL] [Abstract][Full Text] [Related]
18. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic tumor microenvironment in advanced retinoblastoma.
Sudhakar J; Venkatesan N; Lakshmanan S; Khetan V; Krishnakumar S; Biswas J
Pediatr Blood Cancer; 2013 Oct; 60(10):1598-601. PubMed ID: 23804414
[TBL] [Abstract][Full Text] [Related]
20. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
